Study Highlights**WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?**☑All‐case surveillance studies (ACSS) are unique and large postmarketing surveillance studies that are conducted only in Japan; however, limited information is available as to whether ACSS actually provide essential and important information, especially with regard to the revision of package inserts.**WHAT QUESTION DID THIS STUDY ADDRESS?**☑Do industry‐conducted ACSS of newly approved oncology drugs contribute to the revision of package inserts in Japan?**WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?**☑The contribution of ACSS results to the revision of package inserts is limited and at a cost of financial and labor resources.**HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?**☑These results provide new insights into consideration of evaluation of adverse events based on real‐world data in the postmarketing phase in Japan. An automated adverse‐event reporting system is expected.

 {#cts12644-sec-0002}

Cancer is the main cause of death in developed countries, including Japan. More than half of Japanese people are diagnosed with cancer in their lifetime, and the number of cancer deaths is still increasing.[1](#cts12644-bib-0001){ref-type="ref"} Since the beginning of the 21st century, many new types of oncology drugs, not only chemotherapeutics but also targeted drugs and immune checkpoint inhibitors, have been rapidly introduced and approved in Japan. However, a variety of nonhematological toxicities, including serious adverse drug reactions (ADRs), have been observed in patients who were treated with targeted drugs or immune checkpoint inhibitors.[2](#cts12644-bib-0002){ref-type="ref"}, [3](#cts12644-bib-0003){ref-type="ref"} In addition, such kinds of serious ADRs are not fully reported before regular approval by a regulatory agency, and the accelerated approval system for oncology products also limits the information on serious ADRs in postmarketing settings.[4](#cts12644-bib-0004){ref-type="ref"}, [5](#cts12644-bib-0005){ref-type="ref"}

In 1993, the Pharmaceuticals and Medical Devices Agency (PMDA) and Ministry of Health, Labour and Welfare (MHLW) began to request industry‐funded all‐case surveillance studies (ACSS) for orphan drugs, such as anti‐HIV drugs, as a precondition for approval, and required ACSS for irinotecan during the reexamination period as a condition for approval in 1995. ACSS are conducted in Japan to investigate safety and adverse events in all cancer patients to whom most newly approved oncology drugs were prescribed in postmarketing surveillance settings.[6](#cts12644-bib-0006){ref-type="ref"}, [7](#cts12644-bib-0007){ref-type="ref"} There are several objectives of ACSS, including the prompt management of risk and the collection of information on ADRs, to determine the number of patients who use a drug and to understand the actual conditions of the usage of the drug in the real‐world setting. According to an administrative communication, the drugs for which ACSS are necessary for are those that meet following conditions: (i) there are only a small number or no cases of domestic study subjects, and (ii) there are concerns about the drug regarding occurrence of serious ADRs.[7](#cts12644-bib-0007){ref-type="ref"}

However, ACSS are a major burden on the pharmaceutical industry and on clinicians because eventually data on thousands of patients must be collected.[8](#cts12644-bib-0008){ref-type="ref"} The pharmaceutical industry must expend large resources, including a workforce and budget. Clinicians also must spend much time in completing case reports. The ACSS system is a unique and large postmarketing surveillance study system that is conducted only in Japan; however, limited information is available as to whether ACSS actually provide essential and important information, especially with regard to the revision of package inserts, at the cost of huge financial recourses and labor. The objective of this analysis was to investigate whether ACSS can contribute essential new information on severe ADRs that necessitates an addition to or a revision of package inserts of oncology drugs.

Methods {#cts12644-sec-0003}
=======

Drugs for this analysis were selected based on the following criteria: (i) anticancer drugs, (ii) drugs approved in Japan with requirement of ACSS from January 2006--September 2015, and (iii) drugs for which the requirement of ACSS had been removed by September 2015. All approved anticancer drugs were selected, including cytotoxic drugs as well as targeted agents and immune checkpoint inhibitors based on a review of the PMDA website.[9](#cts12644-bib-0009){ref-type="ref"} The package inserts of these drugs were investigated, including the revision records and ACSS reports, to evaluate the influence of the results of ACSS on the revision of package inserts. When the revision records or the ACSS reports were not available, the respective pharmaceutical company in Japan was consulted directly.

Novel treatment‐related adverse events (trAEs) added to a package insert based on ACSS were defined as follows: (i) the trAEs that were newly included in package inserts until removal of conditional approval of ACSS requirement, (ii) the trAEs that were observed in Japan if the information was available, and (iii) the trAEs that were newly reported in the ACSS if the lists of trAEs that were observed in ACSS were available. The removal date was defined as the date on which the description of ACSS as an approval condition was removed from the package insert. Clinically significant trAEs (CS‐trAEs) were defined as trAEs that were included in the "Clinically Significant trAEs" section of the package insert. The data set was analyzed using descriptive statistics, including indication, approval date, planned and registered numbers of patients, study period, removal date, and final report issuance date.

Results {#cts12644-sec-0004}
=======

During the surveillance period for this analysis, 147 anticancer drugs (as indication base) were approved on the basis of an PMDA/MHLW review. ACSS were requested by PMDA/MHLW for 52 indications of these drugs. The approval condition of ACSS was removed for 18 indications by September 2015, including 15 drugs that met the selection criteria (**Table ** [**1**](#cts12644-tbl-0001){ref-type="table"}). The indications of these drugs covered not only rare cancers such as gastrointestinal stromal tumor and mantle cell lymphoma but also common cancers including colorectal cancer, non‐small cell lung cancer, and breast cancer. The planned number of patients per ACSS ranged from 250--4,700. The relationships between the numbers of planned patients and the numbers of actually surveyed patients for safety analysis are shown in **Table ** [**1**](#cts12644-tbl-0001){ref-type="table"} and **Figure ** [**1**](#cts12644-fig-0001){ref-type="fig"}. For most of the drugs, the number of patients for safety analysis was higher than the planned number of patients. In addition, actual ACSS surveillance durations varied widely, from 2.21--6.11 years (**Table ** [**1**](#cts12644-tbl-0001){ref-type="table"}).

###### 

The list of all‐case surveillance studies for 15 drugs (18 indications)

  Brand name (Manufacturer, location, Country)   General name     Indication                                   Approval date   Planned \# of patients   \# of patients for safety analysis   Study period                 Removal date   Duration for ACSS (yr.)   Final report issued date
  ---------------------------------------------- ---------------- -------------------------------------------- --------------- ------------------------ ------------------------------------ ---------------------------- -------------- ------------------------- --------------------------------------------------
  Velcade^®^ (Janssen, Tokyo, Japan)             Bortezomib       MM                                           Oct. 2006       500                      1,010                                Max. 3 years                 Sept. 2011     4.87                      Apr. 2014
  Avastin^®^ (Chugai, Tokyo, Japan)              Bevacizumab      CRC                                          Apr. 2007       2,500                    2,698                                6 months                     Sept. 2010     3.38                      Dec. 2008
  Tarceva^®^ (Chugai, Tokyo, Japan)              Erlotinib        NSCLC                                        Oct. 2007       3,000                    9,909                                12 months                    Feb. 2012      4.29                      Apr. 2013
  Nexaver^®^ (Bayer, Osaka, Japan)               Sorafenib        RCC                                          Jan. 2008       2,000                    3,255                                12 months                    Jun. 2012      4.35                      May. 2015[a](#cts12644-note-0002){ref-type="fn"}
  Nexaver^®^ (Bayer, Osaka, Japan)               Sorafenib        HCC                                          May 2009        4,700                    1,608                                12 months                    Jun. 2015      6.04                      Apr. 2015
  Sutent^®^ (Pfizer, Tokyo, Japan)               Sunitinib        RCC                                          Apr. 2008       600                      1,671                                24 weeks (max. 2 years)      Jul. 2011      3.21                      Mar. 2012
  Sutent^®^ (Pfizer, Tokyo, Japan)               Sunitinib        GIST                                         Apr. 2008       470                      Mar. 2012                                                                                                  
  Eurbitux^®^ (Merck, Tokyo, Japan)              Cetuximab        CRC                                          Jul. 2008       1,800                    2,006                                ---                          Sept. 2012     4.13                      Nov. 2011
  Tasigna^®^ (Novartis, Tokyo, Japan)            Nilotinib        CML[b](#cts12644-note-0003){ref-type="fn"}   Jan. 2009       ---                      ---                                  ---                          Mar. 2014      5.11                      ---
  Sprycel^®^ (BMS, Tokyo, Japan)                 Dasatinib        CML[c](#cts12644-note-0004){ref-type="fn"}   Jan. 2009       800                      897                                  Max. 3 years                 Mar. 2015      6.11                      Sept. 2015
  Doxil^®^ (Janssen, Tokyo, Japan)               Doxorubicin      OC                                           Apr. 2009       500                      2,187                                Max. 10 courses or 1 years   Feb. 2014      4.78                      Sept. 2015
  Tykerb^®^ (Novartis, Tokyo, Japan)             Lapatinib        BreC                                         Apr. 2009       3,000                    4,037                                12 months                    Oct. 2015      6.45                      Oct. 2016
  Afinitor^®^ (Novartis, Tokyo, Japan)           Everolimus       RCC                                          Jan. 2010       1,400                    1,710                                Max. 12 months               Nov. 2012      2.78                      Mar. 2016
  Vectibix^®^ (Takeda, Osaka, Japan)             Panitumumab      CRC                                          Apr. 2010       2,000                    3,086                                10 months                    Jul. 2012      2.21                      Mar. 2013
  Abraxane^®^ (Taiho, Tokyo, Japan)              Nab‐Paclitaxel   BreC                                         Jul. 2010       300                      934                                  6 courses                    Feb. 2013      2.53                      Feb. 2013
  Treakisym^®^ (SymBio, Tokyo, Japan)            Bendamustine     i‐NHL, MCL                                   Oct. 2010       250                      583                                  18 weeks                     Mar. 2013      2.35                      Apr. 2013
  Tarceva^®^ (Chugai, Tokyo, Japan)              Erlotinib        PC                                           Jul. 2011       800                      843                                  Max. 28 weeks                Jul. 2015      4.00                      Oct. 2014
  Gliadel^®^ (Eisai, Tokyo, Japan)               Carmustine       BraC                                         Sept. 2012      250                      558                                  3 months                     Sept. 2015     2.93                      Sept. 2015

‐: Not available, ACSS, all‐case surveillance studies; BraC: brain cancer, BreC: breast cancer, CML: Chronic myelogenous leukemia, CRC: colorectal cancer, GIST: gastro‐intestinal stromal tumor, HCC: hepatocellular carcinoma, i‐NHL: indolent non‐Hodgkin\'s lymphoma, MCL: mantle cell lymphoma, MM: multiple myeloma, NSCLC: non‐small cell lung cancer, OC: ovarian cancer, PC: pancreatic cancer, RCC: renal cell carcinoma, yr.: years.

The indication for Imatinib resistant CML was approved on Jan2009. The indication for CML was approved on DEC2010.

The indication for Imatinib resistant/Philadelphia chromosome‐positive CML was approved on Jan2009. The indication for CML was approved on JUN2011.

Report for discussion with PMDA.

Janssen: Janssen Pharmaceutical K.K., Chugai: Chugai Pharmaceutical Co., Ltd., Bayer: Bayer Yakuhin, Ltd., Pfizer: Pfizer Japan Inc., Merck: Merck biopharma, Novartis: Novartis Pharma K.K, BMS: Bristol‐Myers Squibb K.K., Takeda: Takeda Pharmaceutical Co., Ltd., Taiho: Taiho Pharmaceutical Co., Ltd., SymBio: SymBio Pharmaceuticals Ltd., Eisai: Eisai Co., Ltd.

John Wiley & Sons, Ltd

![Relationship between the numbers of planned patients and actual patients for safety analysis. Dotted blue line indicates identity.](CTS-12-505-g001){#cts12644-fig-0001}

The revision of trAEs in package inserts based on ACSS is shown in **Tables ** [**2**](#cts12644-tbl-0002){ref-type="table"} **and** [**3**](#cts12644-tbl-0003){ref-type="table"} and **Figure ** [**2**](#cts12644-fig-0002){ref-type="fig"}. Median (minimum, maximum) of the number of novel trAEs that were included in package inserts based on ACSS was 7 (0, 32). For doxorubicin and carmustine, no novel trAEs from ACSS were included in the package inserts. Median (minimum, maximum ) of the number of novel CS‐trAEs that were added in package inserts based on ACSS was 1 (0, 21). The ACSS for doxorubicin, lapatinib, nab‐paclitaxel, and carmustine provided no novel CS‐trAEs to package inserts. The package inserts for only six (bortezomib, bevacizumab, erlotinib, cetuximab, panitumumab, and nab‐paclitaxel) of the drugs included incidences of newly observed adverse events, but most of the trAEs and CS‐trAEs were reported based not on summary reports of ACSS but on spontaneous reporting by clinicians.

###### 

Reflection of novel clinically significant (CS) trAEs and novel trAEs to package insert from all‐case surveillance studies

  General name                                                                              Package Insert Revision Date                                                                 Novel CS‐trAE                                                                                                                     Revised Category from NCS‐trAE to CS‐trAE                                                                                                                                                                                                                                               Novel NCS‐trAE
  ----------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Bortezomib                                                                                Ver. 4: Sept. 2008                                                                           Ileus                                                                                                                             ---                                                                                                                                                                                                                                                                                     ---
  Ver. 5: Feb. 2010                                                                         Reversible posterior leukoencephalopathy syndrome                                            ---                                                                                                                               Erythema multiforme, pruritis, impaired urination                                                                                                                                                                                                                                       
  Ver. 6: Sept. 2011[a](#cts12644-note-0006){ref-type="fn"} Removal of approval condition   ---                                                                                          Hepatic disorder                                                                                                                  Hypoglycemia, anxiety, faint, visual disturbance, extra systoles, tachycardia, atrial fibrillation, bradycardia, epistaxis, rhinorrhea, abdominal distension, esophageal reflux                                                                                                         
  Bevacizumab                                                                               Ver. 6: Sept. 2009[a](#cts12644-note-0006){ref-type="fn"}                                    Interstitial pneumonia                                                                                                            ---                                                                                                                                                                                                                                                                                     Dizziness, parosmia, periodontitis, stomach discomfort, gastritis, gingival pains, glossitis, tooth loss, elevated fibrinogen, elevated INR, pruritus, urticarias, nail disorder, pain in extremity, arthralgia, rhinorrhea, glucose urine present, increased CRP, injection site reactions, pneumonia, peripheral edema, complications associated with catheter (infections, inflammations, etc.)[a](#cts12644-note-0006){ref-type="fn"}, hot flush, infections, chest pain, cystitis, herpes zoster, infectious enteritis, increased γ‐GTP, increased FDP, rash
  Ver. 8: Sept. 2010 Removal of approval condition                                          ---                                                                                          ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Erlotinib                                                                                 Ver. 4: Jun. 2009                                                                            Oculo‐mucocutaneous syndrome (Stevens‐Johnson syndrome), erythema multiforme, gastrointestinal perforation, corneal perforation   Corneal ulcer                                                                                                                                                                                                                                                                           Photosensitivity, skin pigmentation
  Ver. 6: Sept. 2010[a](#cts12644-note-0006){ref-type="fn"}                                 Acute kidney injury, gastrointestinal ulceration, gastrointestinal hemorrhage                ---                                                                                                                               Skin fissures, skin ulcer, subcutaneous hemorrhage, skin vasculitis, eye pruritus, eye discharge, blurred vision, anemia, decreased platelet, dry mouth, gastritis, increased amylase, enterocolitis, esophagitis, heartburn, oropharyngeal pain, dizziness, increased blood pressure   
  Ver. 8: Feb. 2012 For NSCLC lifted approval condition                                     ---                                                                                          ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Ver. 11: Sept. 2013                                                                       Severe skin disorder                                                                         ---                                                                                                                                                                                                                                                                                                                                                                                                                       
  Ver. 12: Jul. 2015 For PC Removal of approval condition                                   ---                                                                                          ---                                                                                                                               Hand and foot syndrome[a](#cts12644-note-0006){ref-type="fn"} erythema,[a](#cts12644-note-0006){ref-type="fn"} hematuria[a](#cts12644-note-0006){ref-type="fn"}                                                                                                                         
  Sorafenib                                                                                 Ver. 3: Dec. 2008                                                                            Acute lung injury, interstitial pneumonia                                                                                         ---                                                                                                                                                                                                                                                                                     ---
  Ver. 4: Apr. 2009                                                                         Oculo‐mucocutaneous syndrome (Stevens‐Johnson syndrome)                                      Decreased white blood cell, neutropenia, lymphocytopenia, thrombocytopenia, anemia                                                Flushing, increased LDH, dysgeusia                                                                                                                                                                                                                                                      
  Ver. 6: Sept. 2009                                                                        Renal failure (including acute kidney injury)                                                ---                                                                                                                               Thyroid hyper function disorders                                                                                                                                                                                                                                                        
  Ver. 7: Nov. 2009                                                                         Hepatic failure, hepatic encephalopathy                                                      ---                                                                                                                                                                                                                                                                                                                                                                                                                       
  Ver. 8: Oct. 2010                                                                         Tumor hemorrhage, gastrointestinal ulceration, anaphylactic shock symptoms, rhabdomyolysis   ---                                                                                                                               Radiation recall reaction, hyperkalemia                                                                                                                                                                                                                                                 
  Ver. 9: May 2011                                                                          Fulminant hepatitis, hemorrhagic enterocolitis, ischemic enterocolitis                       ---                                                                                                                               Dizziness, edema                                                                                                                                                                                                                                                                        
  Ver. 10: Apr. 2012                                                                        Toxic epidermal necrolysis                                                                   ---                                                                                                                               Hypocalcaemia                                                                                                                                                                                                                                                                           
  Ver. 11: Jun. 2012 For RCC Removal of approval condition                                  ---                                                                                          ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Ver. 12: Mar. 2013                                                                        Nephrotic syndrome, proteinuria                                                              Hyponatremia                                                                                                                      Hypokalemia                                                                                                                                                                                                                                                                             
  Ver. 15: Jun. 2015 For HCC Removal of approval condition                                  ---                                                                                          ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Sunitinib                                                                                 Ver. 3: Sept. 2009                                                                           Gastrointestinal fistulae, disseminated intravascular coagulation syndromes                                                       ---                                                                                                                                                                                                                                                                                     Hypersensitivity
  Ver. 5: Jan. 2011                                                                         Cerebral hemorrhage, cerebral infarction                                                     ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Ver. 6: Jul. 2011 Removal of approval condition                                           Tumor lysis syndrome                                                                         ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Cetuximab                                                                                 Ver. 2: Mar. 2010                                                                            Heart failures, severe diarrhea                                                                                                   ---                                                                                                                                                                                                                                                                                     ---
  Ver. 4: Sept. 2012[a](#cts12644-note-0006){ref-type="fn"} Removal of approval condition   ---                                                                                          ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Nilotinib                                                                                 Ver. 5: Jan. 2011                                                                            Tumor lysis syndrome                                                                                                              ---                                                                                                                                                                                                                                                                                     ---
  Ver. 7: Jul. 2012                                                                         Peripheral arterial occlusive disease                                                        ---                                                                                                                               Hyperkeratosis, oropharyngeal pain                                                                                                                                                                                                                                                      
  Ver. 9: Apr. 2013                                                                                                                                                                      Hyperglycemia                                                                                                                     ---                                                                                                                                                                                                                                                                                     
  Ver. 10: Mar. 2014 Removal of approval condition                                          Cerebral infarction, transient ischemic attack                                               ---                                                                                                                               Hypertriglyceridemia                                                                                                                                                                                                                                                                    
  Dasatinib                                                                                 Ver. 3: Jul. 2010                                                                            ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     Peripheral neuropathies, atrial fibrillation
  Ver. 5: Oct. 2011                                                                         Pulmonary arterial hypertension                                                              ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Ver. 7: Mar. 2015 Removal of approval condition                                           ---                                                                                          ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Doxorubicin                                                                               Ver. 5: Feb. 2014 Removal of approval condition                                              ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     ---
  Lapatinib                                                                                 Ver. 5: Oct. 2013                                                                            ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     Gastrointestinal ulceration
  Ver. 6: Sept. 2015 Removal of approval condition                                          ---                                                                                          ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Everolimus                                                                                Ver. 2: Mar. 2011                                                                            Renal failure, acute respiratory distress syndrome                                                                                ---                                                                                                                                                                                                                                                                                     Hypocalcaemia, increased blood bilirubin, nail disorder, acnes, arthralgia, proteinuria, increased γ‐GTP, increased ALP
  Ver. 6: Nov. 2012 Removal of approval condition                                           ---                                                                                          ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Panitumumab                                                                               Ver. 8: Jul. 2012 Removal of approval condition                                              ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     ---
  Ver. 10: Mar. 2013[a](#cts12644-note-0006){ref-type="fn"}                                 ---                                                                                          Hypomagnesaemia                                                                                                                   Dysgeusia, cheilitis, constipation, dermatitis, palmar‐plantar erythro‐dysaesthesia syndrome, eczema, thrombocytopenia, leukopenia, hyperkalemia, malaise, Abnormal hepatic function (AST(GOT), AL‐P, LDH, γ‐GTP increased, etc.)                                                       
  Nab‐Paclitaxel                                                                            Ver. 3: Feb. 2013[a](#cts12644-note-0002){ref-type="fn"} Removal of approval condition       ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     Hypoesthesia, muscle spasms, increased potassium, elevated bilirubin, decreased albumin[,a](#cts12644-note-0002){ref-type="fn"} increased blood sugar
  Bendamustine                                                                              Ver. 2: Apr. 2012                                                                            Hepatitis B                                                                                                                       ---                                                                                                                                                                                                                                                                                     ---
  Ver. 3: Mar. 2013 Removal of approval condition                                           ---                                                                                          ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     
  Carmustine                                                                                Ver. 7: Sept. 2015 Removal of approval condition                                             ---                                                                                                                               ---                                                                                                                                                                                                                                                                                     ---

ALP, Alkaline phosphatase; AST, Asparate amino transferase; CRP, C‐reactive protein; CS‐trAE, Clinically significant treatment related adverse event; FDP, Fibrinogen degradation products; GOT, Glutamic oxaloacetic transaminase; HCC, Hepatocellular carcinoma; INR, International normalized ratio; LDH, Lactate dehydrogenase; NCS‐trAE, Non‐clinically significant treatment related adverse event; PI, Package Insert; RCC, Renal cell carcinoma; trAE, Treatment‐related adverse event; γ‐GTP, γ‐glutamyltransferase.

Including numbers of incidence from ACSS in PI.

John Wiley & Sons, Ltd

###### 

Summary of trAEs and CS‐trAEs from all‐case surveillance studies for 15 drugs

  General name     Including numbers of incidence from ACSS   CS‐trAEs   Revised category from NCS‐trAE to CS‐trAE   NCS‐trAEs   Novel trAEs   Novel CS‐trAEs
  ---------------- ------------------------------------------ ---------- ------------------------------------------- ----------- ------------- ----------------
  Bortezomib       Yes                                        2          1                                           15          17            3
  Bevacizumab      Yes                                        1          0                                           31          32            1
  Erlotinib        Yes                                        8          1                                           22          30            9
  Sorafenib        No                                         15         6                                           10          25            21
  Sunitinib        No                                         5          0                                           1           6             5
  Cetuximab        Yes                                        2          0                                           0           2             2
  Nilotinib        No                                         4          1                                           3           7             5
  Dasatinib        No                                         1          0                                           2           3             1
  Doxorubicin      No                                         0          0                                           0           0             0
  Lapatinib        No                                         0          0                                           1           1             0
  Everolimus       No                                         2          0                                           8           10            2
  Panitumumab      Yes                                        0          1                                           11          11            1
  Nab‐Paclitaxel   Yes                                        0          0                                           6           6             0
  Bendamustine     No                                         1          0                                           0           1             1
  Carmustine       No                                         0          0                                           0           0             0
                   Yes: 6, No: 9                              ---        ---                                                     7 (0, 32)     1 (0, 21)

Median (min, max) for number of trAE.

ACSS, All‐case surveillance study, CS‐trAE, Clinically significant treatment related adverse event, NCS‐trAE, Non‐clinically significant treatment related adverse event.

John Wiley & Sons, Ltd

![Number of trAEs and clinically significant trAEs from all‐case surveillance studies for 15 drugs. trAEs, treatment‐related adverse events.](CTS-12-505-g002){#cts12644-fig-0002}

Discussion {#cts12644-sec-0005}
==========

The occurrence of postmarketing ADRs is one of the most important public health problems worldwide. Especially for anticancer drugs, not only hematological toxicities but also nonhematological toxicities have become major concerns with both targeted agents and immune checkpoint inhibitors. Postmarketing surveillance for serious ADRs in many countries is primarily based on a spontaneous reporting system (SRS).[10](#cts12644-bib-0010){ref-type="ref"}, [11](#cts12644-bib-0011){ref-type="ref"}, [12](#cts12644-bib-0012){ref-type="ref"}, [13](#cts12644-bib-0013){ref-type="ref"}, [14](#cts12644-bib-0014){ref-type="ref"} However, whether a voluntary SRS can adequately reveal unreported serious ADRs is controversial. In contrast, the PMDA and MHLW require ACSS especially for selected newly approved drugs, such as anticancer drugs. However, whether this system is working effectively or not remains unclear. According to the ACSS of cetuximab, the incidence and categories of ADRs were not distinct from previous reports.[15](#cts12644-bib-0015){ref-type="ref"}

In the present investigation, the package inserts for only 6 of the drugs included the incidence of newly observed adverse events out of 18 indications of these drugs and 15 drugs that met the selection criteria, but most of the trAEs and CS‐trAEs were reported based not on summary reports of ACSS but on spontaneous reporting by clinicians. The contribution of the ACSS results to the revisions of package inserts is limited, although the framework of ACSS may promote clinicians to conduct intensive reporting of trAEs and CS‐trAEs. The present investigation also shows that the incidence rates of both trAEs and CS‐trAEs are valuable depending on the drug. In addition, the number of patients per ACSS required by the PMDA fluctuates widely, from 500 to thousands of patients, and is based on no clear rule. Not only the issue of ACSS or SRS but also the sample size of postmarketing surveillance is another important point to detect rare but CS‐trAEs or life‐threatening trAEs. The PMDA had requested ACSS in 3,000 patients who were treated by erlotinib, and the final number of patients exceeded 9,000. To our knowledge, there is no published guidance to decide the sample size of ACSS by the PMDA. According to a German investigation, postmarketing studies were not improving drug safety surveillance, and the sample sizes are generally too small to allow the detection of rare ADRs.[16](#cts12644-bib-0016){ref-type="ref"} On the basis of "cost performance," the pharmaceutical industry had paid around ¥30,000 to the hospitals per patient, and more than ¥270,000,000 (\$24,500,000) in total.

Drug‐induced interstitial lung disease was added to the Japanese package insert of sorafenib along with the issuance and distribution of "safety information for acute lung injury/interstitial pneumonia" after approval based on spontaneous reporting by clinicians.[17](#cts12644-bib-0017){ref-type="ref"} Because gefitinib was first approved in Japan for the treatment of non‐small cell lung cancer in July 2002, the drug has been used in patients with non‐small cell lung cancer. Shortly after the approval of gefitinib, however, it was recognized by many clinicians that the drug could cause severe, occasionally fatal, pulmonary damage and/or interstitial lung disease that could not be predicted during registration trials.[18](#cts12644-bib-0018){ref-type="ref"}, [19](#cts12644-bib-0019){ref-type="ref"} The PMDA has become concerned about the induction of interstitial lung disease by targeting agents in Japanese cancer patients and has promoted conduction of ACSS partially because the PMDA did not request ACSS for gefitinib just after approval.

Many serious ADRs may be discovered after a drug receives approval. This suggested a need for continued vigilance and efficient strategies for dissemination of information about ADRs associated with cancer drugs.[20](#cts12644-bib-0020){ref-type="ref"} Healthcare professionals may be more likely to report serious than nonserious adverse drug reactions.[21](#cts12644-bib-0021){ref-type="ref"} One reason a drug may be used for years before risks become evident may be that there is no active drug surveillance system.[22](#cts12644-bib-0022){ref-type="ref"} An automated reporting system is needed to obtain data for a database with an aim for reducing cost and labor.[23](#cts12644-bib-0023){ref-type="ref"} In the United States, Korea, and Japan, the signal detection for adverse events was investigated using databases, including spontaneous adverse event reporting databases.[24](#cts12644-bib-0024){ref-type="ref"}, [25](#cts12644-bib-0025){ref-type="ref"}, [26](#cts12644-bib-0026){ref-type="ref"}, [27](#cts12644-bib-0027){ref-type="ref"} The US Food and Drug Administration launched the "Sentinel Initiative" to expand postmarketing safety data analysis,[28](#cts12644-bib-0028){ref-type="ref"} which is still investigational, especially for anticancer drugs. Careful analysis between the costs of creating extremely large databases and obtaining meaningful clinical information must also be conducted.

One of the pitfalls of the present analysis is that ACSS and SRS could not be compared directly; simulations for both postmarketing surveillance systems may contribute additional knowledge to this important issue. Another point is that most of the trAEs and CS‐trAEs were reported by SRS on the basis of ACSS framework, and ACSS themselves could not be evaluated in those cases.

In conclusion, most of the revisions regarding serious trAEs in package inserts were based on spontaneous reports from clinicians. The contribution of the ACSS results to the revision of package inserts is limited, although the framework of ACSS may promote clinicians to conduct intensive reporting of trAEs and CS‐trAEs. Future investigation is warranted to create an information‐rich and cost‐effective marketing surveillance system, especially for anticancer drugs.
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